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Accreditation in general practice
in Denmark: study protocol for a
cluster-randomized controlled trial
Merethe K. Andersen1*, Line B. Pedersen1,2, Volkert Siersma3, Flemming Bro4, Susanne Reventlow3,
Jens Søndergaard1, Marius Brostrøm Kousgaard3 and Frans B. Waldorff1,3
Abstract
Background: Accreditation is used increasingly in health systems worldwide. However, there is a lack of evidence
on the effects of accreditation, particularly in general practice. In 2016 a mandatory accreditation scheme was
initiated in Denmark, and during a 3-year period all practices, as default, should undergo accreditation according
to the Danish Healthcare Quality Program. The aim of this study is primarily to evaluate the effects of a mandatory
accreditation scheme.
Methods/design: The study is conducted as a cluster-randomized controlled trial among 1252 practices (clusters)
with 2211 general practitioners in Denmark. Practices allocated to accreditation in 2016 serve as the intervention
group, and practices allocated to accreditation in 2018 serve as controls. The selected outcomes should meet the
following criteria: (1) a high degree of clinical relevance; (2) the possibility to assess changes due to accreditation;
(3) availability of data from registers with no self-reporting data. The primary outcome is the number of prescribed
drugs in patients older than 65 years. Secondary outcomes are changes in outcomes related to other perspectives
of safe medication, good clinical practice and mortality. All outcomes relate to quality indicators included in the
Danish Healthcare Quality Program, which is based on general principles for accreditation.
Discussion: The consequences of accreditation and standard-setting processes are generally under-researched,
particularly in general practice. This is the largest study in general practice with a randomized implementation
approach to evaluate the clinical effects of a nation-wide mandatory accreditation scheme in general practice.
Trial registration: ClinicalTrials.gov, NCT02762240. Registered on 24 May 2016.
Keywords: Accreditation, General practice, Clinical effects, Cluster-randomized trial
Background
Accreditation is a procedure in which a recognized exter-
nal institution evaluates an organization on the basis of a
predefined set of quality standards. This usually involves a
formal site visit by a team of surveyors [1]. The evaluation
results in a decision on the granting of accreditation
status. Accreditation has become a widespread tool for
quality control and improvement in healthcare, and many
resources are spent on developing and implementing ac-
creditation systems across the world [2]. Nevertheless,
solid evidence for the effects of accreditation is gener-
ally lacking, and this is particularly true for general
practice [3, 4]. Only two effect studies on accreditation
met the quality standards for inclusion in the first
Cochrane review [5] on the subject, and none of these
studies were about accreditation in general practice.
Further, a review on the status of accreditation in pri-
mary care concluded that there is a dearth of research
on the nature and uptake of accreditation in this sector
along with how accreditation affects outcomes of care,
and whether it is an effective method to improve qual-
ity, perceptions of care, healthcare utilization and costs
[3]. In addition to a call for evidence of the clinical
effects of accreditation, healthcare professionals have
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expressed concerns about the bureaucracy and the
extra registration work imposed by accreditation.
In 2014 it was decided to implement a mandatory
accreditation scheme in Danish general practice in the
period 2016–2018. This protocol paper describes the
design of a cluster-randomized evaluation of this accredit-
ation scheme by means of the Consolidated Standards of
Reporting Trials (CONSORT) extension and the Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) statement for cluster-randomized trials
(Additional files 1 and 2).
Methods/design
Participants and study design
The accreditation scheme in Denmark is rolled out as a
cluster-randomized controlled trial (CRCT). All 1922
general practices are eligible for the study and are allo-
cated to undergo accreditation in 2016, 2017 and 2018
respectively. Practices allocated to accreditation in 2016
(accreditation2016) and representing 604 clusters are
selected as the intervention group, while practices allo-
cated to accreditation in 2018 (accreditation2018) rep-
resent 648 clusters and serve as the control group.
Practices are assigned an accreditation date 1 year in
advance, and in order to avoid contamination from the
intervention group, practices allocated to accreditation
in 2017 (accreditation2017), representing 664 practices,
will be excluded from analysis.
This design, in addition to the comprehensive Danish
National Health registers, offers a unique opportunity to
conduct research on the effects of accreditation [6–8].
Moreover, the design makes possible a comparison of
practices that have already accomplished accreditation
with practices waiting to be accredited [9]. Additionally,
the national Civil Registration System (CRS) facilitates the
collection of relevant data independent of the involved
practices [10].
The Danish healthcare system is tax-financed, and
most general practitioners (GPs) and hospital services
are free of charge. General practice is characterized by
five key components. (1) There is a list system associat-
ing citizens with a GP. GPs can close for uptake when
they have 1600 persons on the list but are allowed to
enroll up to 2550 persons. (2) The GP acts as gate-
keeper and first-line provider in the sense that a referral
from a GP is required for most office-based specialists
and always for inpatient and outpatient hospital treat-
ment. (3) An after-hours system is staffed by GPs on a
rotation basis. (4) There is a mixed capitation and fee-
for-service system. (5) GPs are self-employed, working
on contract for the public funder based on a national
agreement that details not only services and reimburse-
ment but also opening hours and required postgraduate
education [11]. Danish general practice constitutes 1922
practices comprising a total of 3329 GPs.
The accreditation program is developed and managed
by the Danish Institute for Quality and Accreditation in
Healthcare (IKAS). IKAS offers a range of accreditation
programs, tailored for private hospitals, community phar-
macies, community healthcare, general practice and spe-
cialist physicians practicing outside of a hospital setting.
One year in advance, practices are notified about their
accreditation date by letter from IKAS. It is expected that
practices will begin working with the standards from that
date onwards.
Randomization
IKAS decided that surveys in all five regions of Denmark
should be evenly distributed for the 3 years during which
the accreditation process takes place. Moreover, it was de-
cided by IKAS that the accreditation should be conducted
by means of municipalities (each Danish region is divided
into several smaller municipalities) and that the order of
municipalities should be completely random.
Time for accreditation of the practices in the 98 muni-
cipalities in Denmark was determined in a randomized
lots drawing conducted on 22 September 2014 by IKAS,
and provided the basis for a prospective study. Two im-
partial persons from IKAS conducted the drawing.
Within each of the five Danish regions, one-third of the
practices within the municipalities that were drawn first
were allocated to accreditation in 2016, the next third to
2017 and the last third to 2018. If large municipalities
were drawn and this resulted in an excess of practices
greater than one-third of the practices in a region, the
practices were split over 2 allocation years based on the
first letter in the street name in ascending order (Fig. 1).
This randomization allows for comparisons between
early accredited practices (2016, n = 604 practices) and
late accredited practices (2018, n = 648 practices) in
2017. Every practice is considered a cluster, which means
that there are 1252 clusters in the study. The CRCT
study is designed to comply with the recommendations of
the CONSORT statement: extension to cluster-randomized
trials [12] and SPIRIT.
Intervention
Since 2009 accreditation under the Danish Healthcare
Quality Program (DHQP) has been mandatory in the
secondary healthcare system in Denmark, and it was
decided as part of ’the national strategy for quality de-
velopment in the healthcare system – common aims and
plan of action 2002–2006’. The DHQP has been adjusted
to include general practice. The intervention comprises
the rollout of a mandatory accreditation scheme, which
is defined and carried out by an acknowledged, impartial
institution: IKAS.
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The DHQP is based on general principles for ac-
creditation. The model contains a set of accreditation
standards as well as an accreditation process [13]. The
accreditation standards were developed by IKAS in col-
laboration with representatives from the Organization
of General Practitioners in Denmark (PLO), Danish
Regions, Danish Patients, and the Danish Association
of Practicing Medical Specialists. A preliminary version
of the standard set was pilot-tested in 26 practices in
2012 [14]. Subsequently, the standard set was further
adjusted, and the Danish Regions and the PLO approved
the current version in 2014.
The DHQP for general practice consists of 16 standards
with associated indicators within the following areas: (1)
quality and patient safety, (2) patient safety critical
standards, (3) good patient continuity of care and (4)
management and organization [13].
The standards include certain minimal requirements,
but are also written to stimulate quality improvement.
Not everything in the standards is written to describe and
delineate precisely what the client should do. Parts of the
standards are intended to stimulate reflection on one’s
own practice and thereby inspire improvement activities.
Each standard includes a descriptive part, where the
purpose and meaning of the standard is explained in
more or less detail, as appropriate. Furthermore, each
standard includes a number of indicators that comprise
the measurable elements of the standard set. Compli-
ance with the standard set is assessed by rating of the
indicators. The surveyor team does this during survey.
A survey implies a visit from a surveyor team consist-
ing of healthcare professionals who have received spe-
cific training to handle this task. Some surveyors in the
practice sectors are IKAS employees, but all survey
Fig. 1 Trial flow for accreditation in general practice (AKIAP)
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teams will include surveyor(s) who are peers, working
most of their time in healthcare.
The survey has a dual purpose: to assess compli-
ance with minimal requirements and to identify op-
portunities for improvement, even when the threshold
for obtaining accreditation has been reached. A client
needs to comply with the minimal requirements in
order to obtain accreditation. But the survey should
also give the client feedback on his or her efforts to
meet the purpose of the standards, and it should do
this in a way that inspires and supports quality im-
provement work.
Compliance assessment is governed by defined rating
principles. The fundamentals are the same for all
programs:
 Met: The client in all essentials complies with the
requirements in the indicator.
 Largely Met: There are opportunities for
improvement, but accreditation can be awarded;
no further action is required.
 Partially Met: There are opportunities for
improvement, and action is required, unless
accreditation is awarded with comments or,
in case of critical non-compliances, is denied.
 Not Met: There is no evidence for compliance or
only plans to achieve compliance [13].
The standards are accompanied by rating principles, de-
scribing how compliance with the indicators is assessed
and rated [13].
Objectives
The aim of this study is to evaluate the effects of accredit-
ation in general practice with regard to certain clinical
outcomes (Fig. 2).
Clinical outcomes
The selected outcomes should meet the following
criteria: (1) a high degree of clinical relevance, (2) the
possibility to assess changes due to accreditation, (3)
the availability of data independent of self-reporting
from practices. Table 1 lists GPs and practice charac-
teristics. The selected outcomes, their origin from the
DHQP and the used data collection sources are listed
in Table 2.
Fig. 2 SPIRIT flow diagram for the AKIAP project
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Primary outcome
The primary outcome is the changes in number of pre-
scribed drugs in patients older than 65 years between
the baseline and follow-up period.
This outcome refers to standard 2.2 in the DHQP:
physicians in the practice have knowledge about the
basic list for rational pharmacotherapy. The practice
conducts, according to medical judgments, annual con-
trols in patients with chronic disease, comprising as-
sessment of prescriptions.
The primary outcome is selected because inappropri-
ate use of many concurrent drugs, especially in older
people, imposes a substantial burden of adverse drug
events, ill health, disability, hospitalization and even
death. The single most important predictor of inappro-
priate prescribing adverse drug events (ADEs) in older
patients is the number of prescribed drugs [15]. One re-
port estimated the risk of ADE as 13% for two drugs,
38% for four drugs and 82% for seven drugs or more
[15]. A Danish study from 2000 showed that among 75-
year-old persons living at home, 60% used three or more
prescribed drugs and 34% used five or more [16]. A
more recent study performed by the pharmacist founda-
tion found that almost 40% of the elderly older than
65 years use six or more drugs, while this is the case for
more than 50% of the elderly older than 80 years [17].
National guidelines for general practice recommend crit-
ical reviews of the elderly patients’ medication [18], and
secure medication in elderly patients relates to all four
areas in DHQP.
It is not possible to assess whether the medication
given to the individual patient is reasonable, as we have
no access to the patients’ diagnosis or the indication.
Therefore, we will analyse any changes in number of
drugs in elderly persons (older than 65) for accredited
practices and non-accredited practices.
Our main hypothesis is that implementing DHQP will
decrease the number of prescribed drugs during the
accreditation scheme.
Secondary outcomes
The secondary outcomes focus on safe medication prac-
tices, good clinical practices and quality and patient safety
according to the DHQP. These outcomes relate directly to
one of the standards concerning critical patient safety is-
sues (standard 2.2), and they are expressed as changes in
amounts or prevalence between the observation period
and the baseline period.
The rationale for each of the secondary outcomes is
presented in Table 2.
Safe medication Safe medication use includes:
 Changes in the proportion of polypharmacy
(>5 prescribed drugs) patients older than 65 years
 Changes in daily drug dose (DDD) of non-steroidal
anti-inflammatory drugs (NSAIDs) without proton
pump inhibitor (PPI)
 Changes in DDD of sleeping medicine.
Good clinical practice Good clinical practice includes:
 Changes in the proportion of elderly persons older
than 75 receiving a preventive home visit (PHV)
 Changes in the number of annual controls for
chronic disease (ACCD) between periods
 Changes in the number of spirometries performed
 Quality and patient safety:
 Changes in proportion of practices with a reported
adverse event (RAE)
 Changes in proportion of practices with a patient
satisfaction survey between periods.
Mortality Mortality is evaluated as changes in mortality
rates between periods.
Table 1 GP and practice characteristics distributed on
randomization groups
Accreditation
in 2016
Accreditation
in 2018
Total p value χ2 test
GPs 1106 1105 2211
Age
Mean 53.44 52.91 t test: 0.64
Gender 0.32
Male 572 548 1120
(52%) (50%) (51%)
Female 534 557 1091
(48%) (50%) (49%)
Practice type 0.08
Single-handed 314 351 665
(28%) (32%) (30%)
Partnership 792 754 1546
(72%) (68%) (70%)
Region 0.71
Capital 316 330 646
(28%) (30%) (29%)
Central Denmark 272 269 541
(25%) (24%) (25%)
North Denmark 113 94 207
(10%) (9%) (9%)
Zealand 155 157 312
(14%) (14%) (14%)
Southern Denmark 250 255 505
(23%) (23%) (23%)
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Table 2 Description of outcomes according to DHQP standards and data sources
Primary outcome DHQP standard ’aim’ Rationale Data source
Changes in number of prescribed drugs
in patients older than 65 years in period
2.2. Prescriptions and prescription
renewal: “Physicians in the practice have
knowledge about the basic list for rational
pharmacotherapy. The practice conducts,
according to medical judgments, annual
controls in patients with chronic disease,
comprising assessment of prescriptions”.
Inappropriate use of many concurrent
drugs, especially in older people, imposes
a substantial burden of adverse drug
events, ill health, disability, hospitalization,
and even death. National guidelines for
general practice recommend critical
reviews of the elderly patients’
medication, and secure medication in
elderly patients relates to all four areas in
DHQP, but most of all it relates to the
patient security critical standards
Medication
Database (MD)
Secondary outcomes
Polypharmacy in aged patients >65 years
Polypharmacy Yes/No
2.2. Prescriptions and prescription
renewal: “Physicians in the practice have
knowledge about the basic list for rational
pharmacotherapy. The practice conducts,
according to medical judgements, annual
controls in patients with chronic disease,
comprising assessment of prescriptions”.
National guidelines for general practice
recommend critical reviews of the elderly
patients’ medication (18)(18)(18)(15)(19)(18),
and secure medication in elderly patients
relates to all four areas in DHQP, but most
of all it relates to the patient security critical
standards. This variable is the dichotomized
primary outcome defining polypharmacy
as more than 5 concurrent prescribed
medications.
Medication
Database (MD)
Patients >65 years taking NSAIDs without
a concurrent prescription for proton
pump inhibitor (PPI) Daily drug dose
(DDD) of NSAID without PPI in period
2.2. Prescriptions and prescription
renewal: “Physicians in the practice have
knowledge about the basic list for rational
pharmacotherapy. The practice conducts,
according to medical judgements, annual
controls in patients with chronic disease,
comprising assessment of prescriptions”.
Non-steroidal anti-inflammatory drugs
(NSAIDs) can cause serious gastrointes-
tinal complications, and it is estimated
that more than 100 persons die from
NSAID-induced gastrointestinal bleeding
and perforation in Denmark annually. The
risk is higher in the elderly. PPIs reduce
the prevalence of bleeding gastric ulcers
and reduce the risk of dyspepsia and
uncomplicated gastric ulcers in NSAID
treatment. Therefore, PPI treatment is
recommended in combination with
NSAIDs where these are requisite in
patients older than 65 years of age.
Medication
Database (MD)
Sleeping medication Indicator: reduction in
DDD sleeping medication/1000 patients
DDD sleeping medicine in period
2.2. Prescriptions and prescription
renewal: “Physicians in the practice have
knowledge about the basic list for rational
pharmacotherapy. The practice conducts,
according to medical judgements, annual
controls in patients with chronic disease,
comprising assessment of prescriptions”.
National guidelines from the National
Board of Health recommend reduction in
the prescription of sleeping medication.
Medication
Database (MD)
Preventive home visits Indicator: Changes
in percentage of patients >75 years who
have had a preventive home visit
Preventive home visit Yes/No
1.2. Use of good clinical practice –
vulnerable patient groups: “Patients are
diagnosed, treated and provided support
for self care and they are controlled,
referred and rehabilitated in accordance
with good clinical practice”
The care of fragile elderly has a high
priority and is addressed in this standard.
Moreover, a specific fee for conducting
preventive home visits to fragile elderly is
part of the general practice remuneration
system.
The Danish
National Health
Services Register
Annual controls for chronic disease
Indicator: changes in number of
conducted annual controls for chronic
disease/1000 patients Number of annual
controls in period
1.2. Use of good clinical practice –
chronic disease: “Patients are diagnosed,
treated and provided support for self care
and they are controlled, referred and
rehabilitated in accordance with good
clinical practice”
Danish GPs coordinate most of chronic
disease management and conduct annual
controls. Remuneration for annual control
is possible, only once a year, for certain
chronic diseases: diabetes, psychiatric
disease, cardiovascular disease (CVD),
osteoporosis, chronic obstructive
pulmonary disease (COPD), musculoskeletal
disease, dementia and cancer.
The Danish
National Health
Services Register
Spirometry in COPD/asthma Indicator:
changes in number of conducted
spirometry/1000 patients Spirometry
Yes/No in period
1.2. Use of good clinical practice –
chronic disease: “Patients are diagnosed,
treated and provided support for self-care
and they are controlled, referred and reha-
bilitated in accordance with good clinical
practice”
COPD and asthma patients should be
monitored on an annual base with
spirometry. GPs are remunerated with a
certain fee for conducting spirometry.
The Danish
National Health
Services Register
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Data collecting periods
All outcomes except mortality are surveyed in the follow-
ing two periods:
1. Baseline data are collected from 1 January 2014 to
30 June 2014.
2. Follow-up data are collected from 1 January 2017 to
30 June 2017.
For mortality the periods are:
1. Baseline data are collected from 30 June2014 to 31
August 2014.
2. Follow-up data are collected from 30 June 2017 to
31 August 2017.
Data sources
Data on clinical effects measures are prospectively col-
lected and stored within various national registers. How-
ever, the project group does not have permission to
retrieve data until autumn 2017. Prescription data from
2015 formed the basis for the power analysis. Because of
the CRS, these data can be linked to the patients’ civil
registration number and analysed within a common re-
search database hosted by Statistics Denmark (StatDen)
and Statens Serum Institut (SSI). A named responsible
statistician will obtain permission to work with data
within the frames of StatDen.
We will use the National Prescription Register (NPR),
which is a database that includes records of all
prescriptions dispensed at all Danish community
pharmacies since 1995 (information on drugs adminis-
tered to hospital inpatients is not registered) to calcu-
late the number of drugs per patients based on the date
a prescription is redeemed, the pharmaceutical group
(ATC code 4) and the DDD in the redeemed prescrip-
tion. Based on this information, we will calculate the
number of pharmaceutical groups through which an
individual redeemed prescriptions on 30 June in the
years 2014 and 2017.
The Danish Register of Causes of Death (DRCD),
which includes information on specific causes of death
based on death certificates, will be used to define all-
cause mortality.
GP and practice characteristics and services provided
(e.g. spirometry and annual check-ups for chronic condi-
tions) will be retrieved from the Danish National Health
Services Register (DNHSR).
All baseline data are available in the mentioned registers/
databases and will be retrieved starting from autumn 2017.
Statistics
Differences in baseline characteristics are reported as
numbers (percentages) and tested using chi-squared tests.
Linear regression will be used for continuously valued
outcomes (e.g. number of different drugs, safe medication,
annual controls, etc.) and logistic regression for binary
outcomes (polypharmacy, preventive home visits, changes
in proportion of practices with reported adverse events
and changes in proportion of practices with a patient sat-
isfaction survey). Analyses will account for clustering of
patients in practices by generalized estimating equations
Table 2 Description of outcomes according to DHQP standards and data sources (Continued)
Number of reported adverse events
(RAEs) Indicator: changes in number of
RAEs RAE Yes/No in period per practice
1.3. Reported adverse events – the aim of
the standard is to: “Reduce the risk of
patient injuries following adverse events
and to create learning and improvement
on the background of reported adverse
events”.
Reporting of accidental events is
addressed in standard 1.3. It is not only
the aim to reduce the incidence of
accidental events, but also to improve the
management and learning potential of
accidental events. Consequently, a simple
count of RAEs may be equivocal. In order
to avoid bias, we only analyse if at least
one RAE has been reported from a
practice in period.
Danish Patient
Safety Database
(DPSD)
Patient satisfaction survey Changes in
proportion of practices with a patient
satisfaction survey in period
1.4. Patient evaluations – the aim of the
standard is to: “Generate learning and
improve the clinic’s services on the basis of
patient feedback”.
Patient-experienced quality will be
surveyed using data from DANPEP (Danish
Patients Evaluate Practice) (23, 24). DANPEP
is a nationwide, continuous assessment of
patient contentment in general practice.
We only evaluate if a patient satisfaction
survey is conducted in period.
DANPEP database
(Danish Patients
Evaluate Practice).
Mortality Indicator: changes in mortality
rates (deaths/1000 inhabitants) Number
of deaths in 2-month period after index
date
Mortality is the ultimate measure for
effects of all applied interventions in
health sciences. Any changes in mortality
rates in relation to accreditation are of
interest and should be a focus for
analysis. Data on mortality rates can be
obtained from (SD).
Danish Register of
Causes of Death
SD Statistics Denmark (StatDen)
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(GEE). A level of 5% will be taken as statistically
significant.
Analyses will be performed in SAS version 9.4 (SAS
Institute, Cary, NC, USA).
Power calculation
The mean number of Danes older than 65 years allo-
cated to an average practice is 584 (standard deviation
(SD) 378; registry data at the start of 2015). The mean
number of redeemed prescriptions per patient among
Danes older than 65 years is 6.59 (SD 5.04; registry data
over the full year 2014). For the power calculation, the
intra-class correlation (ICC) is set relatively high at 0.2.
Using the formulae in Hemming et al. [19], we are able
with our data to detect a difference from a mean num-
ber of prescriptions of 6.59 in the control group to 6.13
in the accreditation group using a t test with a 5% level
of significance accounting for clustering within practices
with a power of 80%.
Trial status
Randomization has been conducted. Power calculations
are based on prescription data from 2015. All practices
and GPs have been recruited. Data on clinical effects
measures are prospectively collected and stored within
various national registers. However, the project group
does not have permission to retrieve data until autumn
2017.
Discussion
The consequences of accreditation and standard-setting
processes are generally under-researched; this is particu-
larly true in general practice. This paper describes the
rationale and design of the first cluster-randomized con-
trolled trial to evaluate the clinical effects of a nation-
wide accreditation scheme in general practice, focusing
on the effects of accreditation on changes in the number
of prescribed drugs in patients older than 65 years. Our
study is in accordance with several recent calls for more
research into the clinical effects of accreditation in
healthcare [3, 5, 9, 20, 21]. This is the first study with a
CRCT approach to measure clinical effects of accredit-
ation in general practice. Thus, the knowledge emanat-
ing from this study will be unique, and the study may
set a benchmark for more research.
The study is an effectiveness study based on register
data, and thus is not dependent on inputs from partici-
pants or their willingness to participate; hence, the oc-
currence of information and selection bias is reduced.
Moreover, the randomization seems to be successful, as
GPs and their practices do not differ between accredit-
ation years.
Randomization group sizes were dependent on alloca-
tion and determined by IKAS; thus, this decision was out
of the hands of the project group. Allocation was con-
ducted by draw, and the persons who drew lots were im-
partial. The decision on excluding practices allocated to
accreditation in 2017 from the analysis was logical and
pragmatic, as any spillover effect from the intervention
group accreditation year 2016 is suggested to be largest
for accreditation year 2017 and least for accreditation year
2018.
Experiences from the French healthcare system sug-
gest that accreditation risks being reduced to a matter of
standardizing practices rather than a matter of improv-
ing quality [22]. Therefore, our study primarily focuses
on clinically relevant quality indicators relating to the
DHQP. The research group scrutinized the standards in
the accreditation scheme, and the final list of endpoints
was established according to relevant outcomes from a
clinical perspective. The direction of changes for some
of the chosen outcomes is ambiguous; e.g. polypharmacy
can be appropriate in patients with multi-morbidity, but
it may also be a result of a lack of treatment plans and
medicine reviews. However, according to several national
guidelines and systematic reviews, polypharmacy should
be reduced, especially among the elderly.
Because the accreditation scheme is mandatory for all
Danish GPs, the results are expected to be representative
for the effects of accreditation in Danish general prac-
tice. Extrapolation to other countries requires further
consideration due to differences in the organization of
healthcare systems and cultural factors.
The Danish GPs have been informed about the forth-
coming accreditation at least 12 months ahead. It may
be assumed that some practices will prepare their ac-
creditation in good time as part of their practice devel-
opment work. Further, some spillover effects must be
expected from practices undergoing accreditation to
practices awaiting accreditation. Therefore, we collect
baseline data from the first half of 2014, and leave out
the 2017 population in our analysis.
The GPs allocated to the three clusters did not differ
statistically significantly in gender, practice type or region.
Therefore, we assume that eventual changes in perform-
ance cannot be ascribed to selection.
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